Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma

OncoImmunology

Volumn 5, Issue 4, 2016, Pages

  Castino, Giovanni Francesco ^a   Cortese, Nina ^a   Capretti, Giovanni ^a   Serio, Simone ^a   Di Caro, Giuseppe ^a   Mineri, Rossana ^a   Magrini, Elena ^a   Grizzi, Fabio ^a   Cappello, Paola ^b   Novelli, Francesco ^b   Spaggiari, Paola ^a   Roncalli, Massimo ^a   Ridolfi, Cristina ^a   Gavazzi, Francesca ^a   Zerbi, Alessandro ^a   Allavena, Paola ^a   Marchesi, Federica ^a,c  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

B cells; biomarkers; immunotherapy; pancreatic adenocarcinoma (PDAC); tertiary lymphoid tissue

Indexed keywords

ALPHA ENOLASE; CD20 ANTIBODY; CD8 ANTIGEN;

ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CANCER PROGNOSIS; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GERMINAL CENTER; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; RETROSPECTIVE STUDY;

EID: 84962903666     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1085147     Document Type: Article

References (52)

1. R.Siegel, J.Ma, Z.Zou, A.Jemal. Cancer statistics, 2014. CA Cancer J Clin 2014; 64:9-29; PMID:24399786; http://dx.doi.org/10.3322/caac.21208
2. T.Conroy, F.Desseigne, M.Ychou, O.Bouche, R.Guimbaud, Y.Becouarn, A.Adenis, J.L.Raoul, S.Gourgou-Bourgade, C.de la Fouchardiere FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364:1817–25; PMID:21561347; http://dx.doi.org/10.1056/NEJMoa1011923
3. C.E.Clark, S.R.Hingorani, R.Mick, C.Combs, D.A.Tuveson, R.H.Vonderheide. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007; 67:9518–27; PMID:17909062; http://dx.doi.org/10.1158/0008-5472.CAN-07-0175
4. R.H.Vonderheide, L.J.Bayne. Inflammatory networks and immune surveillance of pancreatic carcinoma. Curr Opin Immunol 2013; 25:200–5; PMID:23422836; http://dx.doi.org/10.1016/j.coi.2013.01.006
5. A.Ene-Obong, A.J.Clear, J.Watt, J.Wang, R.Fatah, J.C.Riches, J.F.Marshall, J.Chin-Aleong, C.Chelala, J.G.Gribben Activated pancreatic stellate cells sequester CD8 +T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Gastroenterology 2013; 145:1121–32; PMID:23891972; http://dx.doi.org/10.1053/j.gastro.2013.07.025
6. G.L.Beatty, E.G.Chiorean, M.P.Fishman, B.Saboury, U.R.Teitelbaum, W.Sun, R.D.Huhn, W.Song, D.Li, L.L.Sharp CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011; 331:1612–6; PMID:21436454; http://dx.doi.org/10.1126/science.1198443
7. D.Laheru, E.M.Jaffee. Immunotherapy for pancreatic cancer - science driving clinical progress. Nat Rev Cancer 2005; 5:459–67; PMID:15905855; http://dx.doi.org/10.1038/nrc1630
8. B.C.Ozdemir, T.Pentcheva-Hoang, J.L.Carstens, X.Zheng, C.C.Wu, T.R.Simpson, H.Laklai, H.Sugimoto, C.Kahlert, S.V.Novitskiy Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 2014; 25:719–34; PMID:24856586; http://dx.doi.org/10.1016/j.ccr.2014.04.005
9. S.Ogino, J.Galon, C.S.Fuchs, G.Dranoff. Cancer immunology–analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 2011; 8:711–9; PMID:21826083; http://dx.doi.org/10.1038/nrclinonc.2011.122
10. J.Galon, H.K.Angell, D.Bedognetti, F.M.Marincola. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013; 39:11–26; PMID:23890060; http://dx.doi.org/10.1016/j.immuni.2013.07.008
11. J.Galon, A.Costes, F.Sanchez-Cabo, A.Kirilovsky, B.Mlecnik, C.Lagorce-Pages, M.Tosolini, M.Camus, A.Berger, P.Wind Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960–4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139
12. Di G.Caro, F.Bergomas, F.Grizzi, A.Doni, P.Bianchi, A.Malesci, L.Laghi, P.Allavena, A.Mantovani, F.Marchesi. Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers. Clin Cancer Res 2014; 20:2147–58; PMID:24523438; http://dx.doi.org/10.1158/1078-0432.CCR-13-2590
13. W.H.Fridman, F.Pages, C.Sautes-Fridman, J.Galon. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298–306; PMID:22419253; http://dx.doi.org/10.1038/nrc3245
14. S.Ogino, K.Nosho, N.Irahara, J.A.Meyerhardt, Y.Baba, K.Shima, J.N.Glickman, C.R.Ferrone, M.Mino-Kenudson, N.Tanaka Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res 2009; 15:6412–20; PMID:19825961; http://dx.doi.org/10.1158/1078-0432.CCR-09-1438
15. M.C.Dieu-Nosjean, M.Antoine, C.Danel, D.Heudes, M.Wislez, V.Poulot, N.Rabbe, L.Laurans, E.Tartour, L.de Chaisemartin Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008; 26:4410–7; PMID:18802153; http://dx.doi.org/10.1200/JCO.2007.15.0284
16. D.Coppola, M.Nebozhyn, F.Khalil, H.Dai, T.Yeatman, A.Loboda, J.J.Mule. Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am J Pathol 2011; 179:37–45; PMID:21703392; http://dx.doi.org/10.1016/j.ajpath.2011.03.007
17. A.Cipponi, M.Mercier, T.Seremet, J.F.Baurain, I.Theate, J.van den Oord, M.Stas, T.Boon, P.G.Coulie, N.van Baren. Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res 2012; 72:3997–4007; PMID:22850419; http://dx.doi.org/10.1158/0008-5472.CAN-12-1377
18. G.Di Caro, G.F.Castino, F.Bergomas, N.Cortese, M.Chiriva-Internati, F.Grizzi, A.Mantovani, F.Marchesi. Tertiary lymphoid tissue in the tumor microenvironment: from its occurrence to immunotherapeutic implications. Int Rev Immunol 2015; 34:123–33; PMID:25901857; http://dx.doi.org/10.3109/08830185.2015.1018416
19. L.de Chaisemartin, J.Goc, D.Damotte, P.Validire, P.Magdeleinat, M.Alifano, I.Cremer, W.H.Fridman, C.Sautes-Fridman, M.C.Dieu-Nosjean. Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Res 2011; 71:6391–9; PMID:21900403; http://dx.doi.org/10.1158/0008-5472.CAN-11-0952
20. C.Germain, S.Gnjatic, F.Tamzalit, S.Knockaert, R.Remark, J.Goc, A.Lepelley, E.Becht, S.Katsahian, G.Bizouard Presence of B Cells in Tertiary Lymphoid Structures is Associated with a Protective Immunity in Lung Cancer Patients. Am J Respir Crit Care Med 2014; 189(7):832–44; PMID:24484236; http://dx.doi.org/10.1164/rccm.201309-1611OC.
21. M.C.Dieu-Nosjean, J.Goc, N.A.Giraldo, C.Sautes-Fridman, W.H.Fridman. Tertiary lymphoid structures in cancer and beyond. Trends Immunol 2014; 35(11):571–80; PMID:25443495; http://dx.doi.org/10.1016/j.it.2014.09.006
22. J.Goc, C.Germain, T.K.Vo-Bourgais, A.Lupo, C.Klein, S.Knockaert, L.de Chaisemartin, H.Ouakrim, E.Becht, M.Alifano Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res 2014; 74:705–15; PMID:24366885; http://dx.doi.org/10.1158/0008-5472.CAN-13-1342
23. K.E.de Visser, L.V.Korets, L.M.Coussens. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005; 7:411–23; PMID:15894262; http://dx.doi.org/10.1016/j.ccr.2005.04.014
24. B.H.Nelson. CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol 2010; 185:4977–82; PMID:20962266; http://dx.doi.org/10.4049/jimmunol.1001323
25. G.Bindea, B.Mlecnik, M.Tosolini, A.Kirilovsky, M.Waldner, A.C.Obenauf, H.Angell, T.Fredriksen, L.Lafontaine, A.Berger Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013; 39:782–95; PMID:24138885; http://dx.doi.org/10.1016/j.immuni.2013.10.003
26. N.I.Affara, B.Ruffell, T.R.Medler, A.J.Gunderson, M.Johansson, S.Bornstein, E.Bergsland, M.Steinhoff, Y.Li, Q.Gong B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. Cancer Cell 2014; 25:809–21; PMID:24909985; http://dx.doi.org/10.1016/j.ccr.2014.04.026
27. F.E.Lund, T.D.Randall. Effector and regulatory B cells: modulators of CD4+ T cell immunity. Nat Rev Immunol 2010; 10:236–47; PMID:20224569; http://dx.doi.org/10.1038/nri2729
28. C.Fremd, F.Schuetz, C.Sohn, P.Beckhove, C.Domschke. B cell-regulated immune responses in tumor models and cancer patients. Oncoimmunology 2013; 2(7):e25443; PMID:24073382; http://dx.doi.org/10.4161/onci.25443
29. D.Hannani, C.Locher, T.Yamazaki, V.Colin-Minard, M.Vetizou, L.Aymeric, S.Viaud, D.Sanchez, M.J.Smyth, P.Bruhns Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines. Cell Death Differ 2014; 21:50–8; PMID:23744294; http://dx.doi.org/10.1038/cdd.2013.60
30. S.Shalapour, J.Font-Burgada, Di G.Caro, Z.Zhong, E.Sanchez-Lopez, D.Dhar, G.Willimsky, M.Ammirante, A.Strasner, D.E.Hansel Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature 2015; 521:94–8; PMID:25924065; http://dx.doi.org/10.1038/nature14395
31. Y.Carmi, M.H.Spitzer, I.L.Linde, B.M.Burt, T.R.Prestwood, N.Perlman, M.G.Davidson, J.A.Kenkel, E.Segal, G.V.Pusapati Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity. Nature 2015; 521:99–104; PMID:25924063; http://dx.doi.org/10.1038/nature14424
32. P.Schaerli, K.Willimann, A.B.Lang, M.Lipp, P.Loetscher, B.Moser. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J Exp Med 2000; 192:1553–62; PMID:11104798; http://dx.doi.org/10.1084/jem.192.11.1553
33. D.Breitfeld, L.Ohl, E.Kremmer, J.Ellwart, F.Sallusto, M.Lipp, R.Forster. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med 2000; 192:1545–52; PMID:11104797; http://dx.doi.org/10.1084/jem.192.11.1545
34. K.L.Good-Jacobson, C.G.Szumilas, L.Chen, A.H.Sharpe, M.M.Tomayko, M.J.Shlomchik. PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. Nat Immunol 2010; 11:535–42; PMID:20453843; http://dx.doi.org/10.1038/ni.1877
35. C.Gu-Trantien, S.Loi, S.Garaud, C.Equeter, M.Libin, A.de Wind, M.Ravoet, H.Le Buanec, C.Sibille, G.Manfouo-Foutsop CD4(+) follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest 2013; 123:2873–92; PMID:23778140; http://dx.doi.org/10.1172/JCI67428
36. P.Cappello, S.Rolla, R.Chiarle, M.Principe, F.Cavallo, G.Perconti, S.Feo, M.Giovarelli, F.Novelli. Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer. Gastroenterology 2013; 144:1098–106; PMID:23333712; http://dx.doi.org/10.1053/j.gastro.2013.01.020
37. A.J.Gunderson, L.M.Coussens. B cells and their mediators as targets for therapy in solid tumors. Exp Cell Res 2013; 319(11):1644–9; PMID:23499742; http://dx.doi.org/10.1016/j.yexcr.2013.03.005
38. M.D.Vesely, M.H.Kershaw, R.D.Schreiber, M.J.Smyth. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29:235–71; PMID:21219185; http://dx.doi.org/10.1146/annurev-immunol-031210-101324
39. E.Barbera-Guillem, M.B.Nelson, B.Barr, J.K.Nyhus, May KFJ, L.Feng, J.W.Sampsel. B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion. Cancer Immunol Immunother 2000; 48:541–9; PMID:10630306; http://dx.doi.org/10.1007/PL00006672
40. M.Aklilu, W.M.Stadler, M.Markiewicz, N.J.Vogelzang, M.Mahowald, M.Johnson, T.F.Gajewski. Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. Ann Oncol 2004; 15:1109–14; PMID:15205206; http://dx.doi.org/10.1093/annonc/mdh280
41. F.Martin, A.C.Chan. B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol 2006; 24:467–96; PMID:16551256; http://dx.doi.org/10.1146/annurev.immunol.24.021605.090517
42. O.Thaunat, N.Patey, C.Gautreau, S.Lechaton, V.Fremeaux-Bacchi, M.C.Dieu-Nosjean, E.Cassuto-Viguier, C.Legendre, M.Delahousse, P.Lang B cell survival in intragraft tertiary lymphoid organs after rituximab therapy. Transplantation 2008; 85:1648–53; PMID:18551073; http://dx.doi.org/10.1097/TP.0b013e3181735723
43. A.Schietinger, P.D.Greenberg. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol 2014; 35(2):51–60; PMID:24210163; http://dx.doi.org/10.1016/j.it.2013.10.001
44. S.L.Topalian, C.G.Drake, D.M.Pardoll. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 24:207–12; PMID:22236695; http://dx.doi.org/10.1016/j.coi.2011.12.009
45. A.Gros, P.F.Robbins, X.Yao, Y.F.Li, S.Turcotte, E.Tran, J.R.Wunderlich, A.Mixon, S.Farid, M.E.Dudley PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J Clin Invest 2014; 124:2246–59; PMID:24667641; http://dx.doi.org/10.1172/JCI73639
46. T.F.Gajewski, H.Schreiber, Y.X.Fu. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013; 14:1014–22; PMID:24048123; http://dx.doi.org/10.1038/ni.2703
47. E.R.Lutz, A.A.Wu, E.Bigelow, R.Sharma, G.Mo, K.Soares, S.Solt, A.Dorman, A.Wamwea, A.Yager Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res 2014; 2:616–31; PMID:24942756; http://dx.doi.org/10.1158/2326-6066.CIR-14-0027
48. J.L.Messina, D.A.Fenstermacher, S.Eschrich, X.Qu, A.E.Berglund, M.C.Lloyd, M.J.Schell, V.K.Sondak, J.S.Weber, J.J.Mule. Twelve-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep 2012; 2:765; PMID:23097687; http://dx.doi.org/10.1038/srep00765
49. L.Galluzzi, E.Vacchelli, J.M.Bravo-San Pedro, A.Buque, L.Senovilla, E.E.Baracco, N.Bloy, F.Castoldi, J.P.Abastado, P.Agostinis Classification of current anticancer immunotherapies. Oncotarget 2014; 5:12472–508; PMID:25537519; http://dx.doi.org/10.18632/oncotarget.2998
50. A.Mantovani, P.Allavena. The interaction of anticancer therapies with tumor-associated macrophages. J Exp Med 2015; 212(4):435–45; PMID:25753580; http://dx.doi.org/10.1084/jem.20150295
51. D.G.Altman, L.M.McShane, W.Sauerbrei, S.E.Taube. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med 2012; 9:e1001216; PMID:22675273; http://dx.doi.org/10.1371/journal.pmed.1001216
52. M.B.Eisen, P.T.Spellman, P.O.Brown, D.Botstein. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998; 95:14863–8; PMID:9843981; http://dx.doi.org/10.1073/pnas.95.25.14863